Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acquired hemophilia.

L N Boggio1, D Green

  • 1Division of Hematology/Oncology, Department of Medicine, Northwestern University Medical School, 676 N. St. Clair Street, Chicago, IL 60611, USA.

Reviews in Clinical and Experimental Hematology
|February 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guidelines for assistance to siblings of children with cancer: report of the SIOP Working Committee on Psychosocial Issues in Pediatric Oncology.

Medical and pediatric oncology·1999
Same author

Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.

Journal of medicinal chemistry·1999
Same author

Usefulness of quantitative heel ultrasound compared with dual-energy X-ray absorptiometry in determining bone mineral density in chronic haemodialysis patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·1999
Same author

Risk factors for reduced bone density in haemodialysis patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·1999
Same author

Isolation of Providencia heimbachae from human feces.

Journal of clinical microbiology·1999
Same author

Developmental changes in time estimation: comparing childhood and old age.

Developmental psychology·1999
Same journal

Genomics in hematologic malignancies.

Reviews in clinical and experimental hematology·2006
Same journal

Infections in hematologic patients: the future.

Reviews in clinical and experimental hematology·2006
Same journal

Thrombotic problems in hematologic malignancies.

Reviews in clinical and experimental hematology·2006
Same journal

Prophylaxis and treatment of bacterial infections: do we need new strategies?

Reviews in clinical and experimental hematology·2006
Same journal

Recent developments in new and old viral infections.

Reviews in clinical and experimental hematology·2006
Same journal

Microbiologic consequences of new approaches to managing hematologic malignancies.

Reviews in clinical and experimental hematology·2006
See all related articles

Acquired hemophilia is a rare bleeding disorder caused by autoantibodies against factor VIII. Treatment depends on inhibitor levels, with options including factor concentrates, immunosuppressants, and emerging therapies.

Area of Science:

  • Hematology
  • Immunology
  • Autoimmune Disorders

Background:

  • Acquired hemophilia is a serious coagulopathy.
  • It is caused by autoantibodies targeting factor VIII.
  • Affects elderly, those with autoimmune disorders, and postpartum women.

Purpose of the Study:

  • To review the pathophysiology, diagnosis, and management of acquired hemophilia.
  • To discuss therapeutic strategies for acute bleeding and immune tolerance.

Main Methods:

  • Review of literature on acquired hemophilia.
  • Discussion of diagnostic Bethesda assay.
  • Analysis of treatment options based on inhibitor titers.

Main Results:

Related Experiment Videos

  • Autoantibodies inhibit factor VIII function, leading to bleeding.
  • Bethesda assay quantifies inhibitor strength.
  • Treatment selection is titer-dependent: human factor VIII, porcine factor VIII, recombinant factor VIIa, or activated prothrombin complex concentrates.

    • Conclusions:

    • Corticosteroids, cyclophosphamide, and cyclosporine are key immunosuppressive therapies.
    • Intravenous immunoglobulin and immunosorbent columns offer transient control.
    • New tolerance-inducing strategies are under development.